Anatara Lifesciences Raises $7 Million, Launches Share Purchase Plan To Speed Development Of Detach

Anatara Lifesciences Ltd:Says it has raised $7 million through significantly oversubscribed capital raising to fund international registration and further development of its lead therapy, Detach, a non-antibiotic, natural treatment to treat and prevent diarrhoea in pigs and other livestock animals.Says that Anatara has also announced share purchase plan that it will also offer each eligible shareholder opportunity to subscribe for up to $15,000 in Anatara shares.Says under capital raising, around 9 million fully paid ordinary shares will be issued at a price of $0.78 per share.Says funds raised will be used primarily to carry out parallel registration trials of Detach in Europe and United States.Says funds will also be used to ramp up manufacturing, safety studies, registration in Asia, proof of concept to use Detach in calves and poultry, and advance development of its use in humans.

Help employers find you! Check out all the jobs and post your resume.